Wegovy costs $1,349 in the US vs. $92 in the UK. Why are weight loss drugs so pricey?
About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce risks with obesity.
Drugs like Wegovy, Ozempic would be covered by Medicare, Medicaid under Biden proposal
Millions of Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare and Medicaid under a rule the Biden administration has proposed.
What to Know About Biden’s Plan for Weight-Loss Drugs, Medicaid and Medicare
The Biden administration proposed a rule for Medicare and Medicaid to cover the costs of weight-loss drugs for millions of Americans with obesity.
Biden wants Medicare, Medicaid to cover pricey weight loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
Medicare proposes covering weight-loss drugs, teeing up clash with RFK Jr.
The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden administration said.
Biden Proposes Expanded Medicare, Medicaid Coverage of Obesity Drugs
Current rules for the Medicare and Medicaid government health insurance programs cover the use of drugs such as Mounjaro, Ozempic and Wegovy for certain conditions like diabetes, but not for obesity as a condition on its own.
Biden proposes Medicare, Medicaid cover pricey weight-loss drugs for obese Americans
Millions of Americans could soon have access to weight-loss medications that some have called "miracle drugs."
Biden wants drugs like Wegovy, Ozempic covered by Medicare, Medicaid
Millions of Americans with obesity would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare and Medicaid under a new rule the Biden administration proposed Tuesday morning.
Biden’s plan for Medicare coverage of weight-loss drugs would drive up costs by billions of dollars
President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.
CBC.ca2h
Health Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
Health Canada has approved Novo Nordisk's weight-loss drug Wegovy to reduce the risk of non-fatal heart attack, the ...
Novo Nordisk Is Scaling Back Its Hiring Spree in Denmark
Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...
Wall Street Journal on MSN1d
Novo Nordisk Says White House Obesity Plan Is Step in Right Direction
The Biden administration on Tuesday proposed that weight-loss drugs be paid for by Medicaid and Medicare, potentially making ...
Exclusive-Thousands turn to Wegovy copies each month as FDA considers shortage status
More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...
Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices
A dose of four Wegovy injections will cost 1,400 yuan ($194), a fraction of the drug’s U.S. price, according to the Chinese ...
Bloomberg L.P.2d
Novo Nordisk Foundation Targets US, Europe After Obesity Boost
The Novo Nordisk Foundation’s assets have swelled with the success of diabetes and obesity treatments Ozempic and ...
Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
Novo, Lilly shares rise as Biden proposes obesity care coverage
Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden proposed expanding ...
The Case for Getting the Government to Pay for Wegovy
The Biden administration’s proposal to expand coverage of weight-loss drugs to Medicare and Medicaid recipients is expensive ...